Early trial tests engineered immune cells against tough pancreatic cancer
NCT ID NCT03323944
Summary
This early-phase study tested the safety of a new cell therapy called huCART-meso cells in adults with advanced pancreatic cancer that could not be removed by surgery. The therapy involves collecting a patient's own immune cells (T-cells), modifying them in a lab to better target cancer, and then infusing them back into the body. The main goal was to see if this approach was safe and feasible when given through different methods, including into a vein or directly into the liver or abdomen.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.